U.S. flag

An official website of the United States government

GTR Home > Tests > Guardant Reveal


Test name


Guardant Reveal

Purpose of the test


This is a clinical test intended for Help: Monitoring, Therapeutic management



Click Indication tab for more information.

How to order


Licensed physician contacts Guardant Health client services for ordering information.
Order URL Help: https://www.guardanthealth.com/medical-professionals

Specimen source



Molecular Genetics
MMethylation analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Other
  • None/not applicable
ESequence analysis of select exons
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Other
  • None/not applicable

Summary of what is tested

Click Methodology tab for more information.

Clinical utility


Guidance for management

Clinical validity


A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection.

  • Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, Roeland EJ, Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz A, Boland GM, Corcoran RB. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 Apr 29. doi: 10.1158/1078-0432.CCR-21-0410. Epub ahead of print. PMID: 33926918.

Testing strategy


An approved physician with a Guardant Health account uses the Guardant sample collection kit to obtain a whole blood sample from the patient. Following Guardant shipping instructions, the sample is sent directly to the laboratory at Guardant Health. Turn around time for testing is 7-10 days. 000 Licensed physician contacts Guardant Health client services for ordering information.

Test services

  • Liquid biopsy testing for somatic cancer gene variants

Suggested reading

Practice guidelines

  • EHTG/ESCP, 2021
    European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.